Close Menu

NEW YORK (GenomeWeb) – Thermo Fisher Scientific said today that it has signed an agreement with Eli Lilly and Company to develop a companion diagnostic for Lilly's RET kinase inhibitor, LOXO-292.

The companies plan to use Thermo Fisher's Oncomine Dx Target test, a sequencing panel that is approved by the US Food and Drug Administration, to identify non-small cell lung cancer and thyroid cancer patients with RET alterations who might benefit from LOXO-292.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Dec
19
Sponsored by
Qiagen

This webinar will provide a first-hand look at how a clinical lab evolved its tumor profiling workflow from a targeted panel approach toward comprehensive genomic profiling.  

Jan
28
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.